The nation of Zimbabwe has turned down a substantial US health deal worth 367 million US dollars (272 million pounds) over five years because of the United States' request for sensitive information.
The decision became public after a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
An official spokesperson has since clarified that the United States was seeking genetic material for scientific study and commercial purposes but refused to guarantee the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more negotiations to reach a deal suitable to both sides so the country's critical HIV treatment initiative can be sustained.
Wider Context
This development follows a similar situation in neighbouring Kenya, where a court halted a similar health funding agreement following legal challenges were raised about the safety of Kenyans' health data.
After resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government deals to boost openness and accountability.
Based on reports, Sixteen nations in Africa have to date signed similar health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, without any equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Effectively, our nation would supply the raw materials for scientific discovery with no assurance that the end products would be available to our population should a new disease outbreak arise."
National Interest and Global Health
He also said that the American exit from the global health body and its push of one-on-one health agreements were upending frameworks previously set up via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This mechanism is intended to ensure that when a nation provides its data, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to create them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We encourage continued dialogue with our American counterparts on how future co-operation might be structured in a manner that honours the sovereignty and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but suggested that talks need to persist since much of the country's Aids initiatives relied on international support.
"Where specific concerns arise, including those relating to data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," it said.
This impasse underscores the ongoing tensions between receiving vital foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.